Trends in the surgical treatment of breast cancer

Breast Journal

Volumn 16, Issue SUPPL. 1, 2010, Pages

  Morrow, Monica ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

local control; margins; molecular subtype; surgery

Indexed keywords

PLACEBO; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; HUMAN; MASTECTOMY; PREDICTOR VARIABLE; REVIEW; RISK REDUCTION;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2;

EID: 78649285831     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2010.00996.x     Document Type: Review

References (16)

1. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087 -106.
2. Azu M, Abrahamse P, Katz SJ, et al. What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol 2010; 17: 558 -63.
3. Singletary SE,. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg 2002; 184: 383 -93.
4. Holland R, Veling SH, Mravunac M, Hendriks JH,. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 1985; 56: 979 -90.
5. Sardanelli F, Giuseppetti GM, Panizza P, et al. Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR Am J Roentgenol 2004; 183: 1149 -57.
6. Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 2009; 27: 2466 -73.
7. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001; 345: 1378 -87.
8. Neuschatz AC, DiPetrillo T, Safaii H, et al. Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer 2003; 97: 30 -9.
9. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869 -74.
10. Millar EK, Graham PH, O'Toole SA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 2009; 27: 4701 -8.
11. Wiechmann L, Sampson M, Stempel M, et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 2009; 16: 2705 -10.
12. Kyndi M, Sorensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008; 26: 1419 -26.
13. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008; 26: 2373 -8.
14. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673 -84.
15. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010; 28: 1677 -83.
16. Kaufmann M, Morrow M, Von Minckwitz G, Harris JR,. Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer 2010; 116: 1184 -91.